Biopure, the disgraced developer of a failed human blood substitute, is attempting a comeback. It’s a biotech resurrection that seems quixotic at best. Delusional might be more accurate, given the company’s previous immolation.
On Wednesday, Hemoglobin Oxygen Therapeutics filed a registration statement with the Securities and Exchange Commission, seeking to raise $30 million through an initial public offering. The company name is new, but the blood substitute products it seeks to develop — Hemopure and Oxyglobin — originated with Biopure, which blew up in the mid-2000s and filed for bankruptcy in 2009.